𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gender-based evaluation of the XIENCE V™ everolimus-eluting coronary stent system: : Clinical and angiographic results from the spirit III randomized trial

✍ Scribed by Alexandra J. Lansky; Vivian G. Ng; Halil Mutlu; Ecaterina Cristea; Julian Benetato Guiran; Mark Midei; William Newman; Mark Sanz; Poornima Sood; Julie Doostzadeh; Xiaolu Su; Roseann White; Sherry Cao; Krishnankutty Sudhir; Gregg W. Stone

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
179 KB
Volume
74
Category
Article
ISSN
1522-1946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 1 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat

Evaluation of the effects of everolimus-
Evaluation of the effects of everolimus-eluting and paclitaxel-eluting stents on target lesions with jailed side branches: 2-year results from the SPIRIT III randomized trial
✍ Robert Applegate; James Hermiller; Jerome Williams; Paul Gordon; Julie Doostzade 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

## Abstract Objective: To evaluate whether an everolimus‐eluting stent (EES) with thinner stent struts and polymer results in less periprocedural myonecrosis and adverse outcomes. Background: Higher periprocedural myocardial infarction (MI) rates have been reported with the TAXUS® EXPRESS^2^ paclit